The dark side of C5a in sepsis
Top Cited Papers
- 1 February 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 4 (2) , 133-142
- https://doi.org/10.1038/nri1269
Abstract
Sepsis is a major clinical problem for which therapeutic interventions have been largely unsuccessful, in spite of promising strategies that were successful in animals, especially rodents. There is new evidence that sepsis causes excessive activation of the complement system and that this induces paralysis of innate immune functions in phagocytic cells due to effects of the powerful complement-activation product, C5a. This review describes our present understanding of how and why sepsis is a life-threatening condition and how it might be more effectively treated.Keywords
This publication has 109 references indexed in Scilit:
- Complement and renal diseaseMolecular Immunology, 2003
- Macrophage Migration Inhibitory Factor (MIF)Annals of the New York Academy of Sciences, 2003
- C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathwayKidney International, 2002
- Effects of a new C5a receptor antagonist on C5a- and endotoxin- induced neutropenia in the ratBritish Journal of Pharmacology, 1999
- Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsisCritical Care Medicine, 1998
- Pertussis Toxin-sensitive Activation of Phospholipase C by the C5a and fMet-Leu-Phe ReceptorsJournal of Biological Chemistry, 1996
- C5a-induced expression of P-selectin in endothelial cells.Journal of Clinical Investigation, 1994
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculaturein vitro andin vivoInflammation Research, 1991
- The cobra complement system: I. The alternative pathway of activationDevelopmental & Comparative Immunology, 1985